Physiopathologie de la prééclampsie

Effect of early vitamin D supplementation on the incidence of preeclampsia in primigravid women: a randomised clinical trial in Eastern Democratic Republic of the Congo

BACKGROUND

Previous studies have reported the association between maternal vitamin D deficiency and preeclampsia. However, the efficacy of vitamin D supplementation in reducing the occurrence of preeclampsia remains unclear. The objective of this study was to evaluate the effect of cholecalciferol supplementation on the incidence of preeclampsia in primigravid women and its related maternal and foetal outcomes.

METHODS

A single-blinded clinical trial was conducted in fourteen antenatal care health facilities in the North (Goma, Mwesso, Nyiragongo) and South Kivu (Bukavu-Panzi) provinces of the Democratic Republic of Congo from March 1, 2020, to June 30, 2021. A total of 1300 primigravid women not exceeding 16 weeks of gestation were randomised with a 1:1 ratio to either the supplemented (A) or control (B) group. Each pregnant woman (A) presenting for antenatal care received a single monthly dose of cholecalciferol (60,000 IU) orally for 6 months. The control group received no vitamin D supplementation or placebo. Serum 25(OH)D was measured at recruitment and at 34 weeks of gestation. Outcomes were assessed monthly until delivery.

RESULTS

The median maternal age was 21 years (14-40), while the median gestational age was 15 weeks (5.4-29.0). A significant reduction in the risk of preeclampsia [RR = 0.36 (0.19-0.69); p = 0.001] and preterm delivery [RR = 0.5 (0.32-0.78); p = 0.002] was observed in the intervention group. An RR of 0.43 [(0.27-0.67); p < 0.001] was found for low birth weight. The RR for caesarean section was 0.63 [(0.52-0.75); p < 0.001]. The APGAR score at the 5th minute (p = 0.021) and the size of the newborn were significantly higher in the supplemented group (p = 0.005).

CONCLUSION

A single monthly dose (60,000 IU) of vitamin D supplementation, started in earlypregnancy, significantly reduced the incidence of preeclampsia and its maternal and foetal complications.

TRIAL REGISTRATION

ISRCTN Register with ISRCTN46539495 on 17 November 2020.

Contribution of -1031T/C and -376G/A tumor necrosis factor alpha polymorphisms and haplotypes to preeclampsia risk in Tunisia (North Africa)

Preeclampsia is a gestational disorder characterized by hypertension and proteinuria. Excessive release of pro-inflammatory cytokines, particularly tumour necrosis factor-alpha, has been demonstrated to contribute to endothelial activation and poor trophoblast invasion in placental development, resulting in preeclampsia's clinical symptoms. Genetic polymorphisms of tumour necrosis factor-alpha can regulate its production and may play an important role in the pathogenesis of this disease. This study aimed to evaluate the association of five tumour necrosis factor-alpha gene promoter single nucleotide polymorphisms, or their haplotype combinations, with preeclampsia prevalence. This case-control study was conducted on 300 women with preeclampsia and 300 age-matched women with normal pregnancy from Tunisian hospitals. Genotyping of tumour necrosis factor-alpha -1031 T/C, -376 G/A, -308 G/A, -238 G/A, and +489 G/A SNPs was performed on DNA extracted from blood samples using PCR-restriction fragment-length polymorphism analysis. Statistical analysis was performed using the chi-square test. P < 0.01 were considered statistically significant to take into consideration the multiple comparisons. A significantly higher frequency of the minor allele -1031C (p < 0.001) was observed in preeclampsia cases compared to controls. Notably, the -1031C and -376A (CA) haplotype, which correlates with a higher production of TNF-α protein, had a higher incidence in women with preeclampsia (p = 0.0005). Conversely, the TG haplotype had a low frequency in preeclampsia cases compared to controls (p = 0.002) which suggests that it is associated with a reduced incidence of preeclampsia. These results suggest that tumour necrosis factor-alpha polymorphisms, in particular the -1031C/A, and the haplotype CA, contribute to an increased risk of preeclampsia in Tunisian women.

Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia

Preeclampsia (PE) is a multifactorial pregnancy disease, characterized by new-onset gestational hypertension with (or without) proteinuria or end-organ failure, exclusively observed in humans. It is a leading cause of maternal morbidity affecting 3–7% of pregnant women worldwide. PE pathophysiology could result from abnormal placentation due to a defective trophoblastic invasion and an impaired remodeling of uterine spiral arteries, leading to a poor adaptation of utero-placental circulation. This would be associated with hypoxia/reoxygenation phenomena, oxygen gradient fluctuations, altered antioxidant capacity, oxidative stress, and reduced nitric oxide (NO) bioavailability. This results in part from the reaction of NO with the radical anion superoxide (O₂^•−), which produces peroxynitrite ONOO^-, a powerful pro-oxidant and inflammatory agent. Another mechanism is the progressive inhibition of the placental endothelial nitric oxide synthase (eNOS) by oxidative stress, which results in eNOS uncoupling via several events such as a depletion of the eNOS substrate L-arginine due to increased arginase activity, an oxidation of the eNOS cofactor tetrahydrobiopterin (BH4), or eNOS post-translational modifications (for instance by S-glutathionylation). The uncoupling of eNOS triggers a switch of its activity from a NO-producing enzyme to a NADPH oxidase-like system generating O₂^•−, thereby potentiating ROS production and oxidative stress. Moreover, in PE placentas, eNOS could be post-translationally modified by lipid peroxidation-derived aldehydes such as 4-oxononenal (ONE) a highly bioreactive agent, able to inhibit eNOS activity and NO production. This review summarizes the dysfunction of placental eNOS evoked by oxidative stress and lipid peroxidation products, and the potential consequences on PE pathogenesis.

•

Physiological ROS production is enhanced during pregnancy.

•

eNOS is one of the main target of oxidative stress in PE placenta.

•

eNOS is S-glutathionylated in PE placentas.

•

eNOS is modified by lipid oxidation products in PE placentas.

Immune and Apoptosis Mechanisms Regulating Placental Development and Vascularization in Preeclampsia

Preeclampsia is the most severe type of hypertensive disorder of pregnancy, affecting one in 10 pregnancies worldwide and increasing significantly maternal and neonatal morbidity and mortality. Women developing preeclampsia display an array of symptoms encompassing uncontrolled hypertension and proteinuria, with neurological symptoms including seizures at the end of pregnancy. The main causes of preeclampsia are still unknown. However, abnormal placentation and placenta vascularization seem to be common features in preeclampsia, also leading to fetal growth restriction mainly due to reduced placental blood flow and chronic hypoxia. An over activation of maternal immunity cells against the trophoblasts, the main cells forming the placenta, has been recently shown as an important mechanism triggering trophoblast apoptosis and death. This response will further disrupt the remodeling of maternal uterine arteries, in a first stage, and the formation of new placental vessels in a later stage. A consequent chronic hypoxia stress will further contribute to increase placental stress and exacerbate systemic circulatory changes in the mother. The molecular mechanisms driving these processes of apoptosis and anti-angiogenesis are also not well-understood. In this review, we group main evidences suggesting potential targets and molecules that should be better investigated in preeclampsia. This knowledge will contribute to improve therapies targeting a better placenta formation, having a positive impact on maternal disease prevention and on fetal development.

Association of raised blood lead levels in pregnant women with preeclampsia: A study at tertiary centre

OBJECTIVE

This study aims to find the blood lead levels in pregnant women and its association with pre-eclampsia.

MATERIAL AND METHODS

The study included 44 healthy pregnant females and 23 pre-eclamptic women. Demographic data and common risk factors for lead toxicity were recorded including age, residence, occupation, husband occupation, passive smoking, use of cosmetics, kajal, surma, receiving supplements/vitamins, history of house remodelling, plumbing, source of potable water, paint in house, use of lead-glazed ceramic and pica. Venous blood was collected and lead level was determined by atomic absorption spectrometry.

RESULTS

The mean blood lead level was 2.38 ± 2.43 ug/dL in controls and 3.42 ± 2.18 ug/dL in preeclamptic women which was significantly higher (p = 0.0132). Strong correlation of BLL was observed with blood pressure in pre-eclamptic women. Pre-eclamptic patients were observed to be at increased risk of being lead exposed in terms of occupation and living conditions.

CONCLUSION

Higher blood lead level is associated with increased risk of preeclampsia. Patients should be counselled for lifestyle modification to prevent complications.

Risk factors for eclampsia in pregnant women with preeclampsia and positive neurosensory signs

Objective:

In Morocco, eclampsia remains the second major cause of maternal mortality. Conventionally, patients with preeclampsia and neurosensory signs (NSS) (e.g., headaches and hyperreflexia) are considered at high risk of worsening and progressing to eclampsia. However, this specific population is heterogeneous in terms of eclampsia occurrence. We aimed to identify the risk factors for the development of eclampsia in women with preeclampsia presenting with NSS at admission.

Materials and Methods:

We performed a single-center, retrospective case-control study of patients with preeclampsia with positive NSS from January 1^st, 2012 through December 31^st, 2015, to investigate predictive factors for eclamptic seizures. The case patients were pregnant women with severe preeclampsia who had NSS before developing eclampsia. Control subjects were those with positive NSS without the development of seizures during their hospital stay. One hundred-thirty eight patients with eclampsia and 272 control patients were enrolled.

Results:

Univariate analysis revealed that eclampsia was more likely to develop in patients with the following risk factors: maternal age ≤25 years (χ2=9.58, p=0.002), primiparity (χ2=6.38, p=0.011), inadequate prenatal care (χ2=11.62, p=0.001), systolic hypertension ≥160 mmHg (χ2=15.31, p<0.001), diastolic hypertension ≥110 mmHg (χ2=5.7, p=0.017), generalized acute edema (χ2=14.66, p<0.001), hematocrit <35% (χ2=11.16, p=0.001), serum creatinine >100 μmol/L (χ2=13.46, p<0.001), asparate aminotransferase (AST) >70 IU/L (χ2=10.15, p=0.001), and thrombocytopenia (χ2=22.73, p<0.001). Additionally, independent predictive factors for eclampsia in multivariate analysis included inadequate prenatal care [odds ratio (OR), 8.96 [95% confidence interval (CI): 3.9-20.5], p<0.001), systolic blood pressure ≥160 mmHg (OR, 3.130 [95% CI: 1.342-7.305], p=0.008), thrombocytopenia with a platelet count <50.000 (OR, 13.106 [95% CI: 1.344-127.823], p=0.027), AST ≥70 IU (OR, 3.575 [95% CI: 1.313-9.736], p=0.007), and elevated liver enzymes level, and low platelet count (ELLP) syndrome, which is an incomplete variant of HELLP syndrome (H for hemolysis) (OR, 5.83 [95% CI: 2.43- 13.9], p<0.001).

Conclusion:

This work highlights two major risk factors in this patient population, inadequate prenatal care and ELLP syndrome, which can help in the early identification of patients at highest risk of developing eclampsia and guide preventive measures.

Study of mitochondrial function in placental insufficiency

INTRODUCTION

It has been suggested that mitochondria play a crucial role in sustaining pregnancy and foetal growth. The aim of the study was to assess the influence of mitochondrial functions and genetics on placental insufficiency diseases.

METHODS

A total of 115 patients were recruited, subdivided into 74 placenta samples and 41 maternal blood samples: placental insufficiency diseases including intra uterine growth restriction (IUGR) (n = 35), preeclampsia (PE) (n = 13), IUGR associated to PE (PER) (n = 25); and controls (n = 42). Haplogroups were determined for all patients. Eighty-six placenta samples were studied for quantitative and qualitative analyses of mtDNA: IUGR (n = 25), PE (n = 1), PER (n = 18) and controls (n = 42). Sixteen placenta samples were selected for functional analysis: IUGR (n = 6), PER (n = 2) and controls (n = 8).

RESULTS

Mitochondrial DNA copy numbers and rearrangements and haplogroup distribution were not significantly altered in the patient group. Enzyme activity and expression of respiratory chain complexes were also comparable between both groups.

DISCUSSION

Our results do not argue in favour of a mitochondrial involvement in placental insufficiency, suggesting that the glycolytic pathway may represent a key energetic source in placental insufficiency diseases.

Indicators of Moderate and Severe Preeclampsia in Correlation with Maternal IL10

AIM

The purpose of the actual study was to evaluate the relationship between the formation of anti-inflammatory cytokine IL10 and several indicators of moderate and severe preeclampsia in the third trimester of pregnancy.

MATERIAL AND METHODS

Examination of the indicators of preeclampsia and maternal IL10 levels was conducted in 50 women with pregnancies complicated by varying degrees of preeclampsia in the third trimester of gestation as well as in 50 normotensive patients, hospitalized at the University Clinic of Gynecology and Obstetrics, Skopje, Republic of Macedonia. The levels of IL10 were determined with a commercial test developed by Orgenium Laboratories (Finland), using reagents from AviBion ELISA research kits. Patients with preeclampsia were categorized into moderate and severe preeclampsia group according to the degree of preeclampsia. Logistic regression analysis was used to determine the predictive value of different parameters for the occurrence of severe preeclampsia. Odds ratios and 95% Confidence Intervals were calculated in order to quantify independent associations.

RESULTS

The regression analysis detected systolic blood pressure (160 mmHg or higher), diastolic blood pressure (100 mmHg or higher), persistent proteinuria in pregnancy, serum LDH concentration (450 U/L or higher) and reduced serum concentrations of IL10 as significant predictors of severe preeclampsia in pregnant women after adjusting for age.

CONCLUSION

The findings of significantly lower serum IL10 concentrations in patients with severe preeclampsia in comparison with respective concentrations in patients with moderate preeclampsia can be considered as major pathognomonic laboratory sign of severe preeclampsia.

[Links between preeclampsia and intrauterine growth restriction]

OBJECTIVES

Preeclampsia is one of the most frequent and most serious complications of pregnancy. Its occurrence is around 5% of the pregnancies. Its pathophysiology is complex and includes several hypotheses. Preeclampsia is inconsistently associated with intrauterine growth retardation (IUGR). The determinants that explain the variability of this association are unknown. The objective of our study was to identify in a population of French patients who had preeclampsia and/or HELLP syndrome, incidence and risk factors of IUGR to isolate specific characteristics of these women.

PATIENTS AND METHODS

We studied 578 pregnant women treated for preeclampsia or HELLP syndrome according to the presence or absence of IUGR (database compiled since 1996). Comparisons between the groups were done with Wilcoxon test (quantitative data) or Fisher's exact test (qualitative data).

RESULTS

We found that pre-eclampsia appeared earlier and was more severe in the group with IUGR. In addition foetal issues were more defavorable when IUGR was associated with preeclampsia.

CONCLUSION

Combination of IUGR and pre-eclampsia or HELLP syndrome is a criterion of severity for both the mother and the fetus. Our data do not allow distinguishing physiopathological mechanism to explain these differences.

Alterations of angiopoietin-related growth factor (Angptl6) during pregnancy and in pre-eclampsia

AIM

The aim of this study was to clarify the alterations of angiopoietin-related growth factor (AGF, also known as Angptl6/ARP5) in the serum of normally pregnant women and pre-eclamptic women and to explore the role of AGF in pre-eclampsia.

MATERIAL AND METHODS

Thirty healthy non-pregnant women, 118 normally pregnant women (30 at 6-12 gestational weeks, 30 at 13-28 weeks and 58 at 29-40 weeks, respectively) and 46 pre-eclamptic women were recruited. Fasting blood samples were obtained from all subjects. Fifteen women of healthy pregnant women provided their blood samples at 24 and 48 h after cesarean section, respectively. Enzyme-linked immunosorbent assay was used to determine the serum level of AGF.

RESULTS

Serum levels of AGF were significantly higher in normally pregnant women than non-pregnant women (P < 0.001 of all). Although serum AGF of the first trimester was significantly higher than that of the second trimester (P = 0.033), there were no significant differences of serum AGF in the comparison between the first and third trimester (P = 0.064) and between the second and third trimester (P = 0.546). Serum AGF significantly decreased after delivery (P < 0.05). There were no significant differences in AGF of maternal serum between pre-eclamptic women and normally pregnant control women (P = 0.285). There were no significant differences in circulating AGF concentration between non-pregnant women and postpartum groups (P = 0.052 for 24 h after delivery and P = 0.083 for 48 h after delivery).

CONCLUSION

The serum level of AGF was elevated in normal pregnancy compared with non-pregnant women, suggesting that placenta is an important source of circulating AGF during pregnancy.

In vivo MRI assessment of placental and foetal oxygenation changes in a rat model of growth restriction using blood oxygen level-dependent (BOLD) magnetic resonance imaging

OBJECTIVES

To evaluate whether changes in BOLD signal intensities following hyperoxygenation are related to intrauterine growth restriction (IUGR) in a rat model.

METHODS

IUGR was induced in pregnant rats by ligating the left vascular uterine pedicle at day 16 of gestation. BOLD MR imaging using a balanced steady-state free-precession (balanced-SSFP) sequence on a 1.5-T system was performed on day 19. Signal intensities (SI) before and after maternal hyperoxygenation were compared in the maternal liver and in control and growth-restricted foetoplacental units (FPUs).

RESULTS

Maternal hyperoxygenation resulted in a significant increase in SI in all regions of interest (P < 0.05) in the 18 rats. In the control group, the SI (mean ± SD) increased by 21 % ± 15 in placentas (n = 74) and 13 % ± 8.5 in foetuses (n = 53). In the IUGR group, the increase was significantly lower: 6.5 % ± 4 in placentas (n = 36) and 7 %± 5.5 in foetuses (n = 34) (P < 0.05).

CONCLUSION

BOLD MRI allows non-invasive assessment of the foetoplacental response to maternal hyperoxygenation in the rat and demonstrates its alteration in an IUGR model. This imaging method may provide a useful adjunct for the early diagnosis, evaluation, and management of human IUGR.

KEY POINTS

• Intra-uterine growth restriction is an important cause of perinatal morbidity and mortality. • Blood oxygen level-dependent MRI non-invasively assesses foetoplacental response to maternal hyperoxygenation. • In the rat, foetoplacental response to maternal hyperoxygenation is altered in IUGR. • Functional MRI may help to assess human IUGR.

Reduced placental telomere length during pregnancies complicated by intrauterine growth restriction

Objectives

Recent studies have shown that telomere length was significantly reduced in placentas collected at delivery from pregnancies complicated by intrauterine growth restriction secondary to placental insufficiency. Placental telomere length measurement during ongoing pregnancies complicated by intrauterine growth restriction has never been reported. This was the main objective of our study.

Methods

In our center, late chorionic villus samplings were performed between 18 and 37 weeks of amenorrhea in 24 subjects with severe intrauterine growth restriction (cases) and in 28 subjects with other indications for prenatal diagnosis (controls). Placental insufficiency was assessed by histo-pathological examination. Relative measurement of telomere length was carried out prospectively by quantitative Fluorescent In Situ Hybridization using fluorescent Peptide Nucleic Acid probes on interphase nuclei obtained from long-term cultured villi and with an automated epifluorescent microscope. A quantitative Polymerase Chain Reaction technique was performed to confirm the quantitative Fluorescent In Situ Hybridization results. The number of copies of gene loci encoding the RNA template (hTERC) and the catalytic subunit (hTERT) of the enzyme complex telomerase were also estimated in these placentas by Fluorescent In Situ Hybridization.

Results

Mean fluorescence intensity of telomere probes estimated by quantitative Fluorescent In Situ Hybridization was significantly less for cases compared to controls (p<0.001). This result indicated that mean telomere length was significantly reduced in placentas during pregnancies complicated by intrauterine growth restriction. Reduced telomere length was confirmed by the quantitative Polymerase Chain Reaction technique. No copy number variation of the hTERC and hTERT loci was noticed for cases, or for controls.

Conclusion

This study clearly demonstrates a reduction of placental telomere length in ongoing pregnancies (from 18 to 37 weeks of amenorrhea) complicated by severe intrauterine growth restriction secondary to placental insufficiency.

[Evaluation of D-dimer as a marker for severity in pregnancies with preeclampsia]

OBJECTIVES

Alterations in blood coagulation and fibrinolysis play a major role in the pathogenesis of preeclampsia. HELLP syndrome is associated with hypercoagulability and leads to maternal and perinatal complications. Our purpose was to evaluate D-dimer as a marker for severity in pregnancies with preeclampsia.

PATIENTS AND METHODS

Plasma D-dimer levels were measured using an enzyme-linked immunosorbent assay (ELISA) technique. We studied the association between D-dimer levels and clinical and biological characteristics of pregnancies complicated by preeclampsia.

RESULTS

D-dimer values increased with increasing gestational age. Patients with HELLP syndrome had mean D-dimer values significantly greater than patients with preeclampsia alone (3848±2551 versus 1578±1077, P<0.001). However, the level of D-dimer at the time of admission was poorly predictive of occurrence of HELLP syndrome. Area under of the ROC curve was 0.69 (CI 95%: 0,59-0,79). The best threshold was 2170 ng/mL with a sensitivity of 0.91 and a specificity of 0.40. Other severity criteria of preeclampsia were not associated with higher levels of D-dimer.

DISCUSSION AND CONCLUSION

In preeclamptic patients, D-dimer levels were related with gestational age and HELLP syndrome. However, accuracy of this test to predict occurrence of HELLP syndrome or severe preeclampsia was too low to recommend its use routinely.

[Retinal detachment in preeclampsia: a series of three cases]

Three Afro-Caribbean women presented with a decreased visual acuity associated with preeclampsia during the third trimester of pregnancy. Fundus examination exhibited a serous retinal detachment (SRD). Postpartum fluorescein and indocyanine green angiography indicated subretinal leakage induced by choroidal ischemia. The three patients had an improvement of their visual acuity to 20/20 within 2 to 3 months of the onset of symptoms. Fundus exam and fluorescein angiography showed no further abnormality. SRD in preeclampsia may have an impressive acute presentation but seems to resolve favorably spontaneously without intervention, upon delivery. Nevertheless, SRD must be considered to be a sign of imminent worsening of preeclampsia.

[Pathophysiology of preeclampsia: some recent data]

Placental ischemia is the background of the pathophysiology of preeclampsia. It is mainly - but not exclusively - caused by an immunological conflict between maternal NK cells of the decidua and of the uterine junctional zone, and the HLA-C antigens shared by interstitial trophoblast. The maternal disease is the consequence of the placental ischemia, and is characterized by an inflammatory syndrome with an oxidative stress and an endothelial cell dysfunction. Genetics play an essential part in each of these steps.

[Medical assessment after a pre-eclampsia: why? for whom? when? how? for what purpose?]

The internist has a relevant role in the medical assessment which is mandatory after every case of pre-eclampsia. This postnatal visit has to be performed to assert there is no underlying disorder such as chronic arterial hypertension or nephropathy, autoimmune disease or thrombophilia. This visit is also needed to provide information to the woman about what occurred during the pregnancy as well as to consider which would have to be done in case of a subsequent pregnancy. Long-term outcome had also to be taken into account considering risks for cardiac, arterial, renal and metabolic diseases. This visit is of outmost importance after very early-onset pre-eclampsia, and especially if it has already occurred. The postnatal visit after pre-eclampsia represents a very demonstrative example of the role that the internist can afford to the obstetrician in the management of medical disorders occurring during pregnancy and needing a specific expertise as well as a long-term follow-up.

[Sixty-nine consecutive cases of eclampsia: prodromes and circumstances]

OBJECTIVE

To specify clinical and biological characteristics of patients developing eclampsia, and identify atypical eclampsia without prior signs and symptoms of severe preeclampsia.

PATIENTS AND METHODS

This was a retrospective observational study conducted from January 1996 to December 2008 in a maternity type IIB in French Guiana. Data of patients who experienced eclampsia were collected from obstetric records.

RESULTS

Sixty-nine patients were selected among 21,525 patients who delivered during this period, corresponding to a prevalence of 3.2 ‰. The average patient age was 21 years (range from 12 to 45 years). Sixty-six percent of patients were nulliparous. The gestational age was greater than 37 weeks of gestation for 62% of patients, between 26 and 37 weeks of gestation for 36% and less than 26 weeks of gestation for 2% of patients. Two thirds of the patients had been examined less than a month before the eclamptic seizure, blood pressure was normal in 62% of cases. Seventy-four percent of patients had at least one Doppler study of the uterine and umbilical arteries velocimetry, the Dopplers studies were normal in 78% of cases. The eclampsia occurred in ante-, peri- and post-partum in 59, 6 and 35% of the cases, respectively 10% of patients were hospitalized for preeclampsia at the time of eclamptic seizure. Less than 10% of patients developed HELLP syndrome. One patient had died of aspiration pneumonia. Newborns had a mean birth weight over 2500 g in 88% of cases. During the follow-up period, 41% of the patients had subsequent pregnancies with 62% without hypertension, 24% complicated by recurrent gestational hypertension, 24% by preeclampsia and 4% by eclampsia.

DISCUSSION AND CONCLUSION

In a majority of the patients in our study, eclampsia was the main manifestation, and only 10% were preceded by severe preeclampsia. These results are comparable to recent studies, which found in their series that 40 to 60% of eclampsia manifested without preeclamptic prodromi. Eclampsia can occur after an unremarkable pregnancy, in women without risk factors, and then it is hardly predictable. Prenatal follow-up must be very cautious paying attention to any markers such as intermittent hypertension, functional symptoms or appearance of proteinuria.

[Iron deficiency anemia and pregnancy. Prevention and treatment]

OBJECTIVE

To assess the effectiveness and the safety of prevention and treatment of iron deficiency anemia during pregnancy.

METHODS

French and English publications were searched using PubMed and Cochrane library.

RESULTS

Early screening of iron deficiency by systematic examination and blood analysis seemed essential. Maternal and perinatal complications were correlated to the severity and to the mode of appearance of anemia. Systematic intakes of iron supplements seemed not to be recommended. In case of anemia during pregnancy, iron supplementation was not associated with a significant reduction in substantive maternal and neonatal outcomes. Oral iron supplementation increased blood parameters but exposed to digestive side effects. Women who received parenteral supplementation were more likely to have better hematological response but also severe potential side effects during pregnancy and in post-partum. The maternal tolerance of anemia motivated the choice between parenteral supplementation and blood transfusion.

CONCLUSION

Large and methodologically strong trials are necessary to evaluate the effects of iron supplementation on maternal health and pregnancy outcomes.

Alterations of Serum and Placental Endoglin in Pre-Eclampsia

Serum levels of endoglin were measured in pre-eclamptic women in their third trimester and in women in their second trimester who later developed preeclampsia. Placental levels of endoglin at birth were also determined in preeclamptic women and healthy controls. Serum endoglin was significantly higher in pre-eclamptic women in the third trimester than in controls (median 35.15 versus 10.35 ng/ml, respectively) and in women with severe compared with mild pre-eclampsia (median 51.68 versus 20.99 ng/ml, respectively). Placental endoglin was also significantly higher in pre-eclamptic women than controls (median 26.24 versus 9.21 ng/mg, respectively) and in women with severe compared with mild pre-eclampsia (median 28.77 versus 13.38 ng/mg, respectively). Pregnant women in the second trimester who eventually developed pre-eclampsia had significantly higher serum endoglin than age- and gestational age-matched controls (median 5.90 versus 5.20 ng/ml, respectively). These findings suggest that endoglin plays an important role in the pathogenesis of preeclampsia.